0001213900-23-078927.txt : 20230925 0001213900-23-078927.hdr.sgml : 20230925 20230925080032 ACCESSION NUMBER: 0001213900-23-078927 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20230921 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230925 DATE AS OF CHANGE: 20230925 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Jasper Therapeutics, Inc. CENTRAL INDEX KEY: 0001788028 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 842984849 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39138 FILM NUMBER: 231273149 BUSINESS ADDRESS: STREET 1: 2200 BRIDGE PKWY SUITE #102 CITY: REDWOOD CITY STATE: CA ZIP: 94065 BUSINESS PHONE: 6505491400 MAIL ADDRESS: STREET 1: 2200 BRIDGE PKWY SUITE #102 CITY: REDWOOD CITY STATE: CA ZIP: 94065 FORMER COMPANY: FORMER CONFORMED NAME: Amplitude Healthcare Acquisition Corp DATE OF NAME CHANGE: 20190912 8-K 1 ea185698-8k_jasper.htm CURRENT REPORT
0001788028 false 0001788028 2023-09-21 2023-09-21 0001788028 JSPR:VotingCommonStockParValue0.0001PerShareMember 2023-09-21 2023-09-21 0001788028 JSPR:RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfVotingCommonStockAtExercisePriceOf11.50Member 2023-09-21 2023-09-21 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): September 21, 2023

 

 

 

JASPER THERAPEUTICS, INC.

(Exact Name of Registrant as Specified in its Charter)

 

 

 

 

Delaware

   001-39138   84-2984849
(State or Other Jurisdiction
of Incorporation)		   (Commission File Number)   (IRS Employer
Identification No.)

 

2200 Bridge Pkwy Suite #102
Redwood City, California 94065

(Address of Principal Executive Offices) (Zip Code)

 

(650) 549-1400

Registrant’s telephone number, including area code

 

N/A

(Former Name, or Former Address, if Changed Since Last Report)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Exchange Act:

 

(Title of each class)   (Trading Symbol)   (Name of exchange on which registered)
Voting Common Stock, par value $0.0001 per share   JSPR   The Nasdaq Stock Market LLC
Redeemable Warrants, each whole warrant exercisable for one share of Voting Common Stock at an exercise price of $11.50   JSPRW   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On September 21, 2023, the Board of Directors (the “Board”) of Jasper Therapeutics, Inc. (the “Company”) appointed Herb Cross, age 51, as its Chief Financial Officer and Corporate Secretary. In this role, Mr. Cross is acting as the Company’s principal accounting officer and principal financial officer, effective upon the commencement of his employment with the Company, which was September 22, 2023.

 

Prior to joining the Company, Mr. Cross had served as the Chief Financial Officer of Atreca, Inc., a biotechnology company, since February 2019. From November 2017 to June 2018, he served as Chief Financial Officer of ARMO Biosciences, Inc., a biotechnology company. From February 2016 to November 2017, Mr. Cross served as Chief Financial Officer of Balance Therapeutics, Inc., a biotechnology company. From October 2013 to November 2015, he served as Chief Financial Officer of KaloBios Pharmaceuticals, Inc., a biotechnology company, and interim Chief Executive Officer from January 2015 to November 2015. In December 2015, KaloBios filed a voluntary petition for relief under Chapter 11 of the Bankruptcy Code. KaloBios emerged from Chapter 11 in July 2016. From November 2010 to June 2013, Mr. Cross served as Chief Financial Officer of Affymax, Inc., a biotechnology company. He served as a director of Apexigen, Inc. from July 2022 to August 2023 and Apexigen America, Inc. from October 2019 to August 2023. Mr. Cross received a B.S. in Business Administration from the University of California, Berkeley and is a certified public accountant (inactive).

 

In connection his appointment, the Company entered into an offer letter with Mr. Cross (the “Letter”) on September 19, 2023. Pursuant to the Letter, Mr. Cross’ initial annualized salary is $460,000, he will be eligible to receive a discretionary annual bonus of up to 45% of his base salary, and he will receive a sign on bonus of $100,000. His salary and bonus percentage may be adjusted in the future at the discretion of the Compensation Committee of the Company’s Board. Mr. Cross’ employment will be on an “at will” basis.

 

The Letter provides that Mr. Cross will be granted an option to purchase 550,000 shares of the Company’s voting common stock (the “Option”) pursuant to the Jasper Therapeutics, Inc. Amended and Restated 2022 Inducement Equity Incentive Plan (the “Plan”). The Option was an inducement material to Mr. Cross agreeing to enter into employment with the Company and Mr. Cross has not previously been an employee or director of the Company. The Compensation Committee of the Board approved the Option on September 21, 2023 and the Option was granted pursuant to the Plan on September 22, 2023. The exercise price of the Option is $0.78, the closing sales price of the Company’s voting common stock on the date of grant. The Option will vest over four years, with 25% of the total number of shares vesting on September 22, 2024 and 1/48th of the total number of shares subject to the Option vesting monthly thereafter, subject in each case to Mr. Cross’ continued service to the Company on each vesting date.

 

Mr. Cross does not have any family relationship with any director or executive officer of the Company and there are no related party transactions (as defined in Item 404(a) of Regulation S-K) involving the Company and Mr. Cross. Mr. Cross was not selected to serve as the Company’s Chief Financial Officer pursuant to any arrangement or understanding with any person. The Company has also entered into the Company’s standard form Indemnity Agreement with Mr. Cross. Mr. Cross will be eligible for payments and benefits under the Company’s Employee Severance Plan for Vice Presidents and Executive Committee Members (as may be amended or restated from time to time).

 

On September 21, 2023, in connection with the appointment of Mr. Cross as the Company’s Chief Financial Officer and Corporate Secretary and the Company’s principal financial officer and principal accounting officer, effective September 22, 2023, the Board approved the transition of Jeet Mahal, the Company’s Chief Financial Officer and Chief Operating Officer, to serve solely as the Company’s Chief Operating Officer. In connection with the transition, Mr. Mahal no longer serves as the Company’s Chief Financial Officer, Corporate Secretary, principal financial officer or principal accounting officer.

 

Item 8.01. Other Events.

 

On September 25, 2023, the Company issued a press release announcing the foregoing management changes. A copy of the press release is filed herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

 

99.1

 Press release dated September 25, 2023.
104 Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

  JASPER THERAPEUTICS, INC.
     
Date: September 25, 2023 By: /s/ Ronald Martell
    Name: Ronald Martell
    Title: Chief Executive Officer

 

 

2

 

 

 EX-99.1 2 ea185698ex99-1_jasper.htm PRESS RELEASE DATED SEPTEMBER 25, 2023

Exhibit 99.1

 

 

 

Jasper Therapeutics Appoints Herb Cross as Chief Financial Officer

 

Jeet Mahal Continues as COO

 

REDWOOD CITY, Calif., September 25, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on the development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria (CSU), lower to intermediate risk myelodysplastic syndromes (LR-MDS) as well as novel stem cell transplant conditioning regimens, today announced the appointment of Herb Cross, an experienced senior financial executive, as the company’s Chief Financial Officer (CFO). Jeet Mahal, who previously held both CFO and Chief Operating Officer (COO) roles, will continue as the company’s COO.

 

“We are very pleased to welcome Herb, who brings more than twenty years of public company executive leadership experience to our team, as our new CFO,” said Ronald Martell, Chief Executive Officer of Jasper. “With multiple clinical studies of briquilimab in Chronic Spontaneous Urticaria, Low to Intermediate Risk MDS and hematopoietic stem cell transplant either ongoing or planned to start this year, we are taking the opportunity to strengthen our leadership team in preparation for continued growth. The addition of Herb also allows Jeet Mahal to focus on our increasing operational needs in his ongoing role as our COO.”

 

"I am excited to join Jasper at an important time in its development, particularly given the growing set of compelling data supporting the continued development of briquilimab,” said Herb Cross. “I look forward to building on the company’s strong foundation and am eager to begin working with the leadership team to help realize briquilimab’s potential.”

 

Mr. Cross brings more than two decades of experience in financial leadership roles at both public and private biotechnology companies. Before joining Jasper, he served as CFO at Atreca, leading its initial public offering and holding responsibility for all administrative functions, including finance, corporate communications, human resources and corporate services. Prior to Atreca, he was CFO at ARMO BioSciences, with responsibility for all administrative functions and business development, and led its initial public offering and served as CFO through the sale of the company to Eli Lilly in 2018. Mr Cross also served as CFO and interim Chief Executive Officer at KaloBios Pharmaceuticals, and was CFO at Affymax as well. Mr. Cross began his career at Arthur Andersen, LLP, and received a Bachelor of Science in Business Administration from the Haas School of Business at the University of California, Berkeley. He is a certified public accountant, currently inactive, in the state of California.

 

Mr. Mahal joined Jasper in December 2019 from Portola Pharmaceuticals, where he worked for 11 years and held a number of positions of increasing leadership, most recently as Vice President, Business Development and Vice President, Strategic Marketing. He led the successful execution of multiple business development partnerships for Andexxa®, Bevyxxa® and cerdulatinib. He also played a key role in Portola Pharmaceuticals’ equity financings, including its initial public offering and multiple royalty transactions. Earlier in his career, he was Director, Business and New Product Development, at Johnson & Johnson on the Xarelto® development and strategic marketing team. He started his career in the drug development laboratories at COR Therapeutics.

 

Inducement Grant

 

In connection with the appointment of Mr. Cross as its Chief Financial Officer, on September 22, 2023, Jasper granted Mr. Cross an option to purchase 550,000 shares of its voting common stock (the “Option”). The Option was granted pursuant to the Jasper Therapeutics, Inc. Amended and Restated 2022 Inducement Equity Incentive Plan, as approved by the compensation committee of Jasper’s board of directors on March 14, 2022 and as amended and restated on June 2, 2023, and was granted as an inducement material to Mr. Cross’ employment with Jasper in accordance with Nasdaq Listing Rule 5635(c)(4). The exercise price of the Option is $0.78. The Option will vest over four years, with 25% of the total number of shares vesting on September 22, 2024 and 1/48th of the total number of shares subject to the Option vesting monthly thereafter, subject in each case to Mr. Cross’ continued service to Jasper on each vesting date. Jasper is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).

 

 

 

 

 

About Jasper

 

Jasper is a clinical-stage biotechnology company developing briquilimab, a monoclonal antibody targeting c-Kit (CD117) as a therapeutic for chronic urticaria and lower to intermediate risk myelodysplastic syndromes (MDS) and as a conditioning agent for stem cell transplants for rare diseases such as sickle cell disease (SCD), Fanconi anemia (FA) and severe combined immunodeficiency (SCID). To date, briquilimab has a demonstrated efficacy and safety profile in over 145 dosed patients and healthy volunteers, with clinical outcomes as a conditioning agent in SCID, acute myeloid leukemia (AML), MDS, FA, and SCD. For more information, please visit us at www.jaspertherapeutics.com.

 

Forward-Looking Statements

 

Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding briquilimab’s potential, the development of briquilimab for CSU, LR-MDS and stem cell transplant conditioning and plans to commence multiple clinical studies of briquilimab, briquilimab’s further development and the strategic direction for briquilimab. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of Jasper and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Many actual events and circumstances are beyond the control of Jasper. These forward-looking statements are subject to a number of risks and uncertainties, including general economic, political and business conditions; the risk that the potential product candidates that Jasper develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; the risk that clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release; the risk that Jasper will be unable to successfully market or gain market acceptance of its product candidates; the risk that prior study results may not be replicated; the risk that Jasper’s product candidates may not be beneficial to patients or successfully commercialized; patients’ willingness to try new therapies and the willingness of physicians to prescribe these therapies; the effects of competition on Jasper’s business; the risk that third parties on which Jasper depends for laboratory, clinical development, manufacturing and other critical services will fail to perform satisfactorily; the risk that Jasper’s business, operations, clinical development plans and timelines, and supply chain could be adversely affected by the effects of health epidemics; the risk that Jasper will be unable to obtain and maintain sufficient intellectual property protection for its investigational products or will infringe the intellectual property protection of others; and other risks and uncertainties indicated from time to time in Jasper’s filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2022 and any subsequent Quarterly Reports on Form 10-Q. If any of these risks materialize or Jasper’s assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. While Jasper may elect to update these forward-looking statements at some point in the future, Jasper specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Jasper’s assessments of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.

 

Contacts:

John Mullaly (investors)

LifeSci Advisors

617-429-3548

jmullaly@lifesciadvisors.com

 

Jeet Mahal (investors)

Jasper Therapeutics

650-549-1403

jmahal@jaspertherapeutics.com

 

Lauren Barbiero (media)

Real Chemistry

646-564-2156

lbarbiero@realchemistry.com

 

 

 

 

 

 GRAPHIC 3 ex99-1_001.jpg GRAPHIC begin 644 ex99-1_001.jpg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end EX-101.SCH 4 jspr-20230921.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 5 jspr-20230921_def.xml XBRL DEFINITION FILE EX-101.LAB 6 jspr-20230921_lab.xml XBRL LABEL FILE Class of Stock [Axis] Voting Common Stock, par value $0.0001 per share Redeemable Warrants, each whole warrant exercisable for one share of Voting Common Stock at an exercise price of $11.50 Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 7 jspr-20230921_pre.xml XBRL PRESENTATION FILE XML 8 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover
Sep. 21, 2023
Document Type 8-K
Amendment Flag false
Document Period End Date Sep. 21, 2023
Entity File Number 001-39138
Entity Registrant Name JASPER THERAPEUTICS, INC.
Entity Central Index Key 0001788028
Entity Tax Identification Number 84-2984849
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 2200 Bridge Pkwy Suite #102
Entity Address, City or Town Redwood City
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94065
City Area Code 650
Local Phone Number 549-1400
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
Voting Common Stock, par value $0.0001 per share  
Title of 12(b) Security Voting Common Stock, par value $0.0001 per share
Trading Symbol JSPR
Security Exchange Name NASDAQ
Redeemable Warrants, each whole warrant exercisable for one share of Voting Common Stock at an exercise price of $11.50  
Title of 12(b) Security Redeemable Warrants, each whole warrant exercisable for one share of Voting Common Stock at an exercise price of $11.50
Trading Symbol JSPRW
Security Exchange Name NASDAQ
XML 9 ea185698-8k_jasper_htm.xml IDEA: XBRL DOCUMENT 0001788028 2023-09-21 2023-09-21 0001788028 JSPR:VotingCommonStockParValue0.0001PerShareMember 2023-09-21 2023-09-21 0001788028 JSPR:RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfVotingCommonStockAtExercisePriceOf11.50Member 2023-09-21 2023-09-21 iso4217:USD shares iso4217:USD shares 0001788028 false 8-K 2023-09-21 JASPER THERAPEUTICS, INC. DE 001-39138 84-2984849 2200 Bridge Pkwy Suite #102 Redwood City CA 94065 650 549-1400 false false false false Voting Common Stock, par value $0.0001 per share JSPR NASDAQ Redeemable Warrants, each whole warrant exercisable for one share of Voting Common Stock at an exercise price of $11.50 JSPRW NASDAQ true false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

JQ"(6,P$ "(" / M " ?D0 !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4 " /0#E7)!Z;HJT M #X 0 &@ @ %9$@ >&PO7W)E;',O=V]R:V)O;VLN>&UL M+G)E;'-02P$"% ,4 " /0#E799!YDAD! #/ P $P M@ $^$P 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 "0 ) #X" "(% " ! end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 3 23 1 false 2 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://jaspertherapeutics.com/role/Cover Cover Cover 1 false false All Reports Book All Reports ea185698-8k_jasper.htm jspr-20230921.xsd jspr-20230921_def.xml jspr-20230921_lab.xml jspr-20230921_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ea185698-8k_jasper.htm": { "nsprefix": "JSPR", "nsuri": "http://jaspertherapeutics.com/20230921", "dts": { "inline": { "local": [ "ea185698-8k_jasper.htm" ] }, "schema": { "local": [ "jspr-20230921.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "definitionLink": { "local": [ "jspr-20230921_def.xml" ] }, "labelLink": { "local": [ "jspr-20230921_lab.xml" ] }, "presentationLink": { "local": [ "jspr-20230921_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 1, "axisCustom": 0, "memberStandard": 0, "memberCustom": 2, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 3, "entityCount": 1, "segmentCount": 2, "elementCount": 65, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 26 }, "report": { "R1": { "role": "http://jaspertherapeutics.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2023-09-21", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea185698-8k_jasper.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-09-21", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea185698-8k_jasper.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]" } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "auth_ref": [] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "JSPR_VotingCommonStockParValue0.0001PerShareMember": { "xbrltype": "domainItemType", "nsuri": "http://jaspertherapeutics.com/20230921", "localname": "VotingCommonStockParValue0.0001PerShareMember", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Voting Common Stock, par value $0.0001 per share" } } }, "auth_ref": [] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "JSPR_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfVotingCommonStockAtExercisePriceOf11.50Member": { "xbrltype": "domainItemType", "nsuri": "http://jaspertherapeutics.com/20230921", "localname": "RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfVotingCommonStockAtExercisePriceOf11.50Member", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Redeemable Warrants, each whole warrant exercisable for one share of Voting Common Stock at an exercise price of $11.50" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001213900-23-078927-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-23-078927-xbrl.zip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end